Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash from Investing Activities (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Cash from Investing Activities for 10 consecutive years, with -$13.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Investing Activities changed N/A year-over-year to -$13.3 million, compared with a TTM value of -$84.1 million through Sep 2025, down 23729.49%, and an annual FY2024 reading of $356000.0, up 367.67% over the prior year.
  • Cash from Investing Activities was -$13.3 million for Q3 2025 at Avalo Therapeutics, up from -$70.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $356000.0 in Q1 2024 and bottomed at -$70.9 million in Q2 2025.
  • Average Cash from Investing Activities over 5 years is -$9.3 million, with a median of -$56000.0 recorded in 2022.
  • The sharpest move saw Cash from Investing Activities fell 28.57% in 2021, then soared 367.67% in 2024.
  • Year by year, Cash from Investing Activities stood at -$11000.0 in 2021, then tumbled by 254.55% to -$39000.0 in 2022, then tumbled by 241.03% to -$133000.0 in 2023, then skyrocketed by 367.67% to $356000.0 in 2024, then tumbled by 3825.0% to -$13.3 million in 2025.
  • Business Quant data shows Cash from Investing Activities for AVTX at -$13.3 million in Q3 2025, -$70.9 million in Q2 2025, and $356000.0 in Q1 2024.